ZVRA Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -296.76% compared to Zevra Therapeutics's net margin of 32.59%. Zevra Therapeutics's return on equity of -208.85% beat Eli Lilly and's return on equity of 80.24%.

Zevra Therapeutics has a consensus price target of $21.63, signalling upside risk potential of 207.17%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 36.88%. Given that Zevra Therapeutics has higher upside potential than Eli Lilly and, analysts believe Zevra Therapeutics is more attractive than Eli Lilly and.

Zevra Therapeutics has a beta of 1.938, which suggesting that the stock is 93.751% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zevra Therapeutics quarterly revenues are $12M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Zevra Therapeutics's net income of -$35.7M is lower than Eli Lilly and's net income of $4.4B. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 63.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 13.79x versus 14.82x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

SIGA Technologies has a net margin of -296.76% compared to Zevra Therapeutics's net margin of 56.17%. Zevra Therapeutics's return on equity of -208.85% beat SIGA Technologies's return on equity of 32.37%.

Zevra Therapeutics has a consensus price target of $21.63, signalling upside risk potential of 207.17%. On the other hand SIGA Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Zevra Therapeutics has higher upside potential than SIGA Technologies, analysts believe Zevra Therapeutics is more attractive than SIGA Technologies.

Zevra Therapeutics has a beta of 1.938, which suggesting that the stock is 93.751% more volatile than S&P 500. In comparison SIGA Technologies has a beta of 1.023, suggesting its more volatile than the S&P 500 by 2.284%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SIGA Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.60 per share. Zevra Therapeutics pays -- of its earnings as a dividend. SIGA Technologies pays out 72.05% of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zevra Therapeutics quarterly revenues are $12M, which are smaller than SIGA Technologies quarterly revenues of $81.5M. Zevra Therapeutics's net income of -$35.7M is lower than SIGA Technologies's net income of $45.8M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while SIGA Technologies's PE ratio is 6.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 13.79x versus 2.79x for SIGA Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Alpha Teknova has a net margin of -296.76% compared to Zevra Therapeutics's net margin of -61.73%. Zevra Therapeutics's return on equity of -208.85% beat Alpha Teknova's return on equity of -31.69%.

Zevra Therapeutics has a consensus price target of $21.63, signalling upside risk potential of 207.17%. On the other hand Alpha Teknova has an analysts' consensus of $10.67 which suggests that it could grow by 135.04%. Given that Zevra Therapeutics has higher upside potential than Alpha Teknova, analysts believe Zevra Therapeutics is more attractive than Alpha Teknova.

Zevra Therapeutics has a beta of 1.938, which suggesting that the stock is 93.751% more volatile than S&P 500. In comparison Alpha Teknova has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alpha Teknova offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Alpha Teknova pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $12M, which are larger than Alpha Teknova quarterly revenues of $9.3M. Zevra Therapeutics's net income of -$35.7M is lower than Alpha Teknova's net income of -$5.7M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Alpha Teknova's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 13.79x versus 5.79x for Alpha Teknova. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -296.76% compared to Zevra Therapeutics's net margin of -549.33%. Zevra Therapeutics's return on equity of -208.85% beat Voyager Therapeutics's return on equity of -21.07%.

Zevra Therapeutics has a consensus price target of $21.63, signalling upside risk potential of 207.17%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 421.04%. Given that Voyager Therapeutics has higher upside potential than Zevra Therapeutics, analysts believe Voyager Therapeutics is more attractive than Zevra Therapeutics.

Zevra Therapeutics has a beta of 1.938, which suggesting that the stock is 93.751% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.773%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $12M, which are larger than Voyager Therapeutics quarterly revenues of $6.3M. Zevra Therapeutics's net income of -$35.7M is lower than Voyager Therapeutics's net income of -$34.5M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 13.79x versus 2.23x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.